adamantane has been researched along with Diabetes Mellitus in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (22.22) | 29.6817 |
| 2010's | 12 (66.67) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Dudka, J; Gawrońska-Grzywacz, M; Herbet, M; Piątkowska-Chmiel, I; Popiołek, Ł | 1 |
| Andou, S; Hase, M; Ishizawa, F; Kishikawa, Y; Ojima, F; Sakurai, J; Satoh, J; Satoh, S; Takahashi, T | 1 |
| Cohen, D | 1 |
| Goto, C; Mizui, T; Ohta, H; Tachi, T; Teramachi, H; Toyoshima, M; Tsuchiya, T | 1 |
| Hirata, T; Ito, T; Kurita, N; Shimizu, S; Uchihara, H | 1 |
| Sugita, M | 1 |
| Caffrey, JL; Chang, CH; Chang, YC; Chuang, LM; Lai, MS; Lin, JW; Wu, LC | 1 |
| Kimura, K; Takayanagi, R; Uchida, T; Yamada, Y | 1 |
| Everhart, D; Meah, Y; Rascati, KL; Worley, K | 1 |
| De Meester, I; Lambeir, AM; Scharpé, S | 1 |
| Miuchi, M; Miyagawa, J; Nanba, M | 1 |
| Buikema, H; de Boer, RA; Oeseburg, H; Silljé, HH; van der Harst, P; van Gilst, WH | 1 |
| Döller, D; Haidinger, M; Hecking, M; Hörl, WH; Pleiner, J; Säemann, MD; Stemer, G; Voigt, HC; Weichhart, T; Werzowa, J | 1 |
| Chung, CC; Ellsworth, KP; Karanam, BV; Lassman, ME; Lee, SH; Li, C; Miller, C; Myers, RW; Powles, M; Salituro, G; Singh, SB; Tota, MR; Wang, J; Wu, M; Zhang, BB | 1 |
| Fonseca, VA | 1 |
| Döller, D; Frantal, S; Haidinger, M; Hecking, M; Lechner, F; Pacini, G; Pleiner, J; Säemann, MD; Stemer, G; Werzowa, J | 1 |
4 review(s) available for adamantane and Diabetes Mellitus
| Article | Year |
|---|---|
DPP4 inhibitors for diabetes--what next?
Topics: Adamantane; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Hypoxia; Neoplasms; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2008 |
[Incretin related agents for treatment of diabetes mellitus].
Topics: Adamantane; Diabetes Mellitus; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2009 |
[Pharmacological sheet. Vildagliptin, oral administration (GALVUS)].
Topics: Adamantane; Contraindications; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Nitriles; Pyrrolidines; Vildagliptin | 2009 |
Ongoing clinical trials evaluating the cardiovascular safety and efficacy of therapeutic approaches to diabetes mellitus.
Topics: Adamantane; Cardiovascular System; Clinical Trials as Topic; Diabetes Mellitus; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drugs, Investigational; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Risk Assessment; Risk Reduction Behavior | 2011 |
2 trial(s) available for adamantane and Diabetes Mellitus
| Article | Year |
|---|---|
A randomized, placebo-controlled, double-blind, prospective trial to evaluate the effect of vildagliptin in new-onset diabetes mellitus after kidney transplantation.
Topics: Adamantane; Austria; Biomarkers; Blood Glucose; Clinical Protocols; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Kidney Transplantation; Nitriles; Placebo Effect; Prospective Studies; Pyrrolidines; Research Design; Time Factors; Treatment Outcome; Vildagliptin | 2010 |
Vildagliptin and pioglitazone in patients with impaired glucose tolerance after kidney transplantation: a randomized, placebo-controlled clinical trial.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glucose Intolerance; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Kidney Transplantation; Male; Middle Aged; Nitriles; Outcome Assessment, Health Care; Pioglitazone; Pyrrolidines; Risk Factors; Thiazolidinediones; Treatment Outcome; Vildagliptin | 2013 |
12 other study(ies) available for adamantane and Diabetes Mellitus
| Article | Year |
|---|---|
The novel adamantane derivatives as potential mediators of inflammation and neural plasticity in diabetes mice with cognitive impairment.
Topics: Adamantane; Animals; Brain-Derived Neurotrophic Factor; Cognitive Dysfunction; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Dopamine Agents; Humans; Inflammation; Inflammation Mediators; Mice; Neuronal Plasticity | 2022 |
[Efficacy of Saxagliptin for Blood Glucose Control in Hemodialysis Patients with Diabetes].
Topics: Adamantane; Aged; Aged, 80 and over; Blood Glucose; Cost Savings; Diabetes Mellitus; Dipeptides; Drug Substitution; Female; Glycated Serum Albumin; Glycation End Products, Advanced; Humans; Linagliptin; Male; Middle Aged; Pilot Projects; Pyrazoles; Renal Dialysis; Serum Albumin; Thiazolidines | 2020 |
Reports of pancreatitis are 20-30 times more likely with GLP-1 drugs, analysis finds.
Topics: Adamantane; Diabetes Mellitus; Dipeptides; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Linagliptin; Pancreatitis; Purines; Pyrazines; Quinazolines; Sitagliptin Phosphate; Triazoles; United States | 2013 |
Pharmacoeconomic analysis of DPP-4 inhibitors.
Topics: Adamantane; Clinical Trials as Topic; Cohort Studies; Cost-Benefit Analysis; Costs and Cost Analysis; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Nitriles; Piperidines; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2013 |
Idiosyncratic liver injury induced by vildagliptin with successful switch to linagliptin in a hemodialyzed diabetic patient.
Topics: Adamantane; Aged; Chemical and Drug Induced Liver Injury; Diabetes Mellitus; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Linagliptin; Nitriles; Purines; Pyrrolidines; Quinazolines; Renal Dialysis; Vildagliptin | 2014 |
[The perception gap between clinical trials and clinical practice].
Topics: Adamantane; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Weight; Diabetes Mellitus; Humans; Male; Nitriles; Olanzapine; Pyrrolidines; Schizophrenia; Vildagliptin | 2015 |
No increased risk of hospitalization for heart failure for patients treated with dipeptidyl peptidase-4 inhibitors in Taiwan.
Topics: Adamantane; Aged; Cohort Studies; Diabetes Mellitus; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Nitriles; Pyrrolidines; Risk Factors; Sitagliptin Phosphate; Taiwan; Treatment Outcome; Vildagliptin | 2016 |
Evaluation of drug efficacy of DPP-4 inhibitors based on theoretical analysis with pharmacokinetics and pharmacodynamics.
Topics: Adamantane; Algorithms; Area Under Curve; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Nitriles; Piperidines; Pyrrolidines; Treatment Outcome; Uracil; Vildagliptin | 2017 |
Adherence, Persistence, and Health Care Costs for Patients Receiving Dipeptidyl Peptidase-4 Inhibitors.
Topics: Adamantane; Aged; Aged, 80 and over; Diabetes Mellitus; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Health Care Costs; Humans; Hypoglycemic Agents; Insulin; Linagliptin; Male; Managed Care Programs; Medication Adherence; Middle Aged; Sitagliptin Phosphate | 2017 |
Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A.
Topics: Adamantane; Animals; Cells, Cultured; Cellular Senescence; Cyclic AMP; Cyclic AMP Response Element-Binding Protein; Cyclic AMP-Dependent Protein Kinases; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; DNA Damage; Dose-Response Relationship, Drug; Endothelial Cells; Enzyme Activation; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Heme Oxygenase-1; Humans; Hydrogen Peroxide; Hypoglycemic Agents; Male; NAD(P)H Dehydrogenase (Quinone); Nitriles; Oxidants; Oxidative Stress; Peptides; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrrolidines; Rats; Rats, Zucker; Reactive Oxygen Species; Receptors, Glucagon; Signal Transduction; Venoms; Vildagliptin | 2010 |
Antidiabetic and antisteatotic effects of the selective fatty acid synthase (FAS) inhibitor platensimycin in mouse models of diabetes.
Topics: Adamantane; Aminobenzoates; Anilides; Animals; Anti-Infective Agents; Diabetes Mellitus; Disease Models, Animal; Fatty Acid Synthases; Fatty Acids; Fatty Liver; Glucose; Humans; Hypoglycemic Agents; Liver; Mice; Mice, Mutant Strains; Oxidation-Reduction; Sterols | 2011 |
Molecule of the month. Vildagilptin.
Topics: Adamantane; Diabetes Mellitus; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin Resistance; Nitriles; Pyrrolidines; Randomized Controlled Trials as Topic; Vildagliptin | 2006 |